MeteoWeb
A better discount within the danger of main adversarial cardiovascular occasions (cardiovascular dying, non-fatal coronary heart assault or non-fatal stroke) has been skilled by therapy with the semaglutide 2,4 mg in individuals with cardiovascular illnesses related to weight problems or obese. This was revealed by the “Select” examine, launched in 2018 by the pharmaceutical firm Novo Nordisk and illustrated in the present day on the European Congress on Obesity (ECO), underway in Venice.
At week 20 of therapy with semaglutide 2.4 mg, topics who achieved 5% or extra weight reduction in comparison with those that achieved much less weight reduction had related reductions in coronary heart illness danger. Previous information from the Select trial recommended that cardiovascular occasions could also be improved by various mechanisms past weight reduction alone. Event danger discount was achieved no matter weight stage, physique mass index, waist circumference, and waist-to-height ratio.
To date, semaglutide 2.4 mg is the one GLP-1 receptor agonist that has demonstrated cardiovascular advantages in individuals with weight problems and related heart problems. Previous outcomes had proven a 20% danger discount and 9.4% common physique weight discount in comparison with placebo. It was additionally demonstrated, for a interval of as much as 5 years, that the chance discount was unbiased of age, intercourse, and ethnicity.
Select is a randomized, double-blind, parallel-group, placebo-controlled examine designed to judge the efficacy of semaglutide 2.4 mg versus placebo as an adjunct to plain look after the prevention of cardiovascular occasions in individuals with established illness, obese or overweight and with no historical past of diabetes, for a interval of 5 years. The individuals included within the examine had been over the age of 45. The examine enrolled 17,604 adults and was performed in 41 nations at greater than 800 trial websites.
Continue studying on MeteoWeb